✦ LIBER ✦

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

✍ Scribed by Michael Boeckh; Raleigh A. Bowden; Barry Storer; Nelson J. Chao; Ricardo Spielberger; D. Kathryn Tierney; Ghislaine Gallez-Hawkins; Terri Cunningham; Karl G. Blume; Daniel Levitt; John A. Zaia

Book ID: 117727889
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 957 KB
Volume: 7
Category: Article
ISSN: 1083-8791
DOI: 10.1016/s1083-8791(01)80005-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Maribavir prophylaxis for prevention of

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

✍ Francisco M Marty; Per Ljungman; Genovefa A Papanicolaou; Drew J Winston; Roy F 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 259 KB

CMX001 for Prevention and Control of CMV

CMX001 for Prevention and Control of CMV Infection in CMV-Seropositive Allogeneic Stem-Cell Transplant Recipients: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial of Safety, Tolerability and Antiviral Activity

✍ F.M. Marty; D. Winston; S.D. Rowley; M. Boeckh; E. Vance; G. Papanicolaou; A. Ro 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 100 KB